



UNITED STATES PATENT AND TRADEMARK OFFICE

AB

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/695,065	10/25/2000	Michael A. Brasch	0942.5000001/RWE/BJD	1682
26111	7590	10/27/2004	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			LU, FRANK WEI MIN	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 10/27/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/695,065	Applicant(s) BRASCH ET AL.	
	Examiner Frank W Lu	Art Unit 1634	✓

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 23 June 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 14-20, 27, and 30-57 is/are pending in the application.
- 4a) Of the above claim(s) 40-43 and 52-55 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 14-20, 27, 30-39, 44-51, 56, and 57 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- | | |
|--|--|
| 15) <input type="checkbox"/> Notice of References Cited (PTO-892) | 18) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 16) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 19) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 17) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>6/1004</u> | 20) <input type="checkbox"/> Other: |

DETAILED ACTION

Response to Amendment

1. Applicant's response to the office action filed on June 23, 2004 has been entered. The claims pending in this application are claims 14-20, 27, and 32-57 wherein claims 40-43 and 52-55 has been withdrawn due to restriction requirement. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the amendments. The following rejections are based on amendments and claims 14-20, 27, 32-39, 44-51, 56, and 57 will be examined.

Claim Objections

2. Claim 14 is objected to because of the following informality: "one or more integration sequence-containing nucleic molecules" in line 5 should be "one or more integration sequence-containing nucleic acid molecules" in order to correspond to one or more integration sequence-containing nucleic acid molecules in line 6.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 56 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1634

5. Claim 56 recites the limitation “said second nucleic acid comprising said transferred first segment” in the claim. There is insufficient antecedent basis for this limitation in the claim since claim 44 describes that “transferring said first segment from said first nucleic acid molecule to said second nucleic acid molecule” and the second nucleic acid recited in step (b) of claim 44 does not have said transferred first segment. Please clarify.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(c) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(f) he did not himself invent the subject matter sought to be patented.

7. Claims 14-20, 27, 32, 33, 44-46, and 57 are rejected under 35 U.S.C. 102(b) as being anticipated by Stemmer (US Patent No. 5,605,793, published by February 25, 1997).

Stemmer teaches method for *in vitro* recombination which can be used in many different genes encoded proteins.

Regarding claim 14, according to the specification, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid

Art Unit: 1634

molecule” (see the specification, page 22, last paragraph bridging to page 23, first paragraph), “recombination site” is defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see page 25, last paragraph), and “recombinant protein” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph). Stemmer teaches inserting one or more double-stranded oligonucleotides comprising one or more mutations into double-stranded random fragments, denaturing the resultant mixture of the double-stranded random fragments and oligonucleotides into single-stranded fragments, incubating the resultant population of single-stranded fragments with a polymerase under conditions which results in the annealing of said single-stranded fragments at regions of identity between the single-stranded fragments and formation of a mutagenized double-stranded polynucleotide (see column 3, second paragraph). Since one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer is capable of inserting randomly into a target nucleic acid molecule (ie., one or more double-stranded random fragments), one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer is one or more integration sequences as recited in claim 14. Since one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer are inserted into one or more double-stranded random fragments in the presence of a polymerase and form a mutagenized double-stranded polynucleotide, one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer contain one or more recombination sites as recited in claim 14. Therefore, Stemmer discloses inserting one or more integration sequences (ie., one or more double-stranded oligonucleotides

Art Unit: 1634

comprising one or more mutations) comprising at least one recombination site into at least one nucleic acid molecule (ie., double-stranded random fragments) to produce one or more integration sequence-containing nucleic acid molecules as recited in claim 14. Since the mutagenized double-stranded polynucleotide taught by Stemmer is cloned into an appropriate vector (see column 8, lines 60 and 61) and it is known that a cloning process must used a ligase, according to the definition of “recombination protein” in the specification, a ligase is a recombination protein and Stemmer discloses transferring one or more integration sequence-containing nucleic acid molecules formed in the inserting step comprising at one recombination site into one or more vectors in the presence of one or more recombination proteins (ie., a ligase) as recited in claim 14.

Regarding claims 16 and 18, according to the specification, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule” (see the specification, page 22, last paragraph bridging to page 23, first paragraph), “recombination site” is defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see page 25, last paragraph), and “recombinant protein ” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph). Stemmer teaches inserting one or more double-stranded oligonucleotides comprising one or more mutations into double-stranded random fragments, denaturing the resultant mixture of the double-stranded random fragments and oligonucleotides into single-stranded fragments, incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of said single-stranded fragments at

Art Unit: 1634

regions of identity between the single-stranded fragments and formation of a mutagenized double-stranded polynucleotide (see column 3, second paragraph). Since one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer is capable of inserting randomly into a target nucleic acid molecule (ie., one or more double-stranded random fragments), one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer is one or more integration sequences as recited in claim 16. Since one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer are inserted into one or more double-stranded random fragments in the presence of a polymerase and form a mutagenized double-stranded polynucleotide, one or more double-stranded oligonucleotides comprising one or more mutations taught by Stemmer contain one or more recombination sites as recited in claim 16. Therefore, Stemmer discloses inserting one or more integration sequences (ie., one or more double-stranded oligonucleotides comprising one or more mutations) comprising at least one recombination site into at least one nucleic acid molecule (ie., double-stranded random fragments) as recited in claim 16. Since, after restriction digestion, the digested mutagenized double-stranded polynucleotide taught by Stemmer is cloned into an appropriate vector (see column 8, lines 60 and 61 and column 12) and it is known that a cloning process must used a ligase, according to the definition of "recombination protein" in the specification, the digested mutagenized double-stranded polynucleotide taught by Stemmer is an integration sequence-containing nucleic acid molecule comprising at least first and second recombination sites as recited in claim 16 wherein 5' and 3' ends of restriction sites of the digested mutagenized double-stranded polynucleotide are a first and a second recombination site and Stemmer discloses causing said at least first and second

Art Unit: 1634

recombination sites to recombine in the presence of at least one recombination protein (ie., a ligase) as recited in claim 16. Since Stemmer teaches that 5' and 3' ends of restriction sites of the digested mutagenized double-stranded polynucleotide are a first and a second recombination site, Stemmer discloses that said first and second recombination sites are separated by a portion of said integration sequence-containing nucleic acid molecule as recited in claim 18.

Regarding claims 15 and 27, since double-stranded random fragments are generated from a PCR product of the wild-type LacZ alpha gene (see column 11), the double-stranded random fragments are genomic DNA as recited in claims 15 and 27.

Regarding claim 17, since an appropriate vector taught by Stemmer is a plasmid such as pUC 18 (see column 12, lines 13-67) and it is known that a plasmid is a circular molecule, Stemmer discloses that said recombination of said first and second recombination sites insert into the vector and results in a circular molecule as recited in claim 17.

Regarding claims 19 and 20, since the oligonucleotides comprising one or more mutations taught by Stemmer can be single stranded and it is known that a single stranded nucleic acid can be labeled with P^{32} at the 5' end in the presence of T4 polynucleotide kinase. According to the definition of "selectable markers" in the specification (see page 26, last paragraph bridging to page 27, first paragraph), selectable markers are DNA segments that bind products that modify a substrate, the oligonucleotides comprising one or more mutations taught by Stemmer are DNA segments that bind product that modify a substrate (ie., T4 polynucleotide kinase) or one or more selective markers as recited in claims 19 and 20.

Regarding claims 32 and 33, since Stemmer teaches that said first and second recombination sites are 5' and 3' ends of restriction sites (see above), Stemmer discloses that

Art Unit: 1634

said first and second recombination sites are site-specific recombination sites as recited in claims 32 and 33.

Regarding claim 44, according to the specification, "integration sequence" is defined as "any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule" (see the specification, page 22, last paragraph bridging to page 23, first paragraph), "recombination site" is defined as "a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins" (see page 25, last paragraph), and "recombinant protein" is defined as "proteins that are involved in recombination reactions involving one or more recombination sites" (see the specification, page 25, second paragraph). Stemmer teaches to digest a PCR product with restriction enzymes BamHI and Eco0109 and ligates digested PCR product into pUC18 digested with BamHI and Eco0109 (see column 12, lines 6-67). Since 3' and 5' of the digested PCR product taught by Stemmer has restriction sites, Stemmer discloses a first nucleic acid molecule comprising at least a first segment which comprises at least a first and a second recombination site (ie., 3' and 5' restriction sites of the digested PCR product), wherein said segment comprises at least one integration sequence as recited in step (a) of claim 44. Since 5' and 3' ends of pUC18 contain restriction sites, Stemmer discloses a second nucleic acid molecule comprising at least a third and fourth recombination site (ie., 5' and 3' restriction sites of pUC18) as recited in steps (b) and (c) of claim 44. Since, during the ligation reaction, the digested PCR product must mix with pUC18 digested with BamHI and Eco0109 in the presence of a ligase, Stemmer discloses forming a mixture by mixing said first nucleic acid molecule (ie., the digested PCR product with at least one second nucleic acid molecule comprising at least a third and fourth recombination

Art Unit: 1634

site (ie., pUC18 digested with BamHI and Eco0109) in the presence of at least one recombination protein (ie., a ligase) and incubating said mixture under conditions favoring recombination at least between said first (ie., the BamHI site on the digested PCR product) and third recombination sites (the BamHI site on the digested pUC18) and at least between said second (ie., the Eco0109 site on the digested PCR product) and fourth recombination sites (ie., the Eco0109 site on the digested pUC18), thereby transferring said first segment (ie., the digested PCR product) from said first nucleic acid molecule to said second nucleic molecule (ie., the digested pUC18) as recited in steps (b) and (c) of claim 44.

Regarding claims 45 and 46, since 3' and 5' of the digested PCR product taught by Stemmer has restriction sites (see above), Stemmer teaches that said first segment (ie., the digested PCR product) is flanked on one side by said first recombination site and is flanked on the other side by said second recombination site as recited in claim 45 wherein said first, second, third and fourth recombination sites are site-specific recombination sites as recited in claim 46.

Regarding claim 57, since the ligation reaction taught by Stemmer is performed in *in vitro* (see column 12, lines 6-67), Stemmer discloses that said recombination (ie., the ligation taught by Stemmer) takes place *in vitro* as recited in claim 57.

Therefore, Stemmer teaches all limitations recited by claims 14-20, 27, 32, 33, 44-46, and 57.

Response to Arguments

In page 16, first paragraph bridging to page 19, first paragraph of applicant's remarks, applicant argued that: (1) "[S]temmer does not disclose recombination sites as recited in the present claims" in view of the definition of "recombination site"; and (2) "[S]temmer also fails

Art Unit: 1634

to disclose recombination proteins according to the present invention” in view of the definition of “site-specific recombinases”.

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. First, since “recombinant protein” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph), the ligase taught by Stemmer is a recombination protein. Second, although site-specific recombinases are proteins that are present in many organisms (e.g., viruses and bacteria) and have been characterized as having endonuclease and ligase properties (see the specification, page 2, first paragraph), the rejected claims do not require site-specific recombinases. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

8. Claims 14-20, 27, 32, 33, 44-46, and 57 are rejected under 35 U.S.C. 102(b) as being anticipated by Atlung *et al.*, (Gene 107, 11-7, October 1991).

Atlung *et al.*, teach a versatile method for integration of modified genes and gene fusions into the bacteriophage lambda attachment site (attB) of the *Escherichia coli* chromosome.

Regarding claim 14, according to the specification, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule” (see the specification, page 22, last paragraph bridging to page 23, first paragraph), “recombination site” is defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see page 25,

Art Unit: 1634

last paragraph), and “recombinant protein ” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph). Atlung *et al.*, teach to construct plasmid pTAC3599 by cloning a 740-bp Taq I fragment containing the promoter appYp into the Sama I site of pTAC3575 (see Figure 1 in page 12). Since the restriction sites of the 740-bp Taq I fragment containing the promoter appYp is recombination sites, Atlung *et al.*, disclose inserting one or more integration sequences comprising at least one recombination site (ie., the 740-bp Taq I fragment containing the promoter appYp) into at least one nucleic acid molecule (ie., pTAC3575) to produce one or more integration sequence-containing nucleic acid molecules as recited in claim 14. Since Atlung *et al.*, teach to ligate the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion to the purified BstEII-Sal I fragment carrying the attP-aphA cassette from pTAC3463 (see page 13, left column and Figure 2 in page 14) and it is known that a ligation reaction must be performed in the presence of a ligase, Atlung *et al.*, disclose transferring one or more integration sequence-containing nucleic acid molecules (ie., the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion) comprising recombination sites (ie., restriction sites of the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion) into one or more vectors (ie., the purified BstEII-Sal I fragment carrying the attP-aphA cassette from pTAC3463) in the presence of one or more recombination proteins (ie. the ligase) as recited in claim 14.

Regarding claims 16 and 18, according to the specification, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule” (see the specification, page 22, last paragraph bridging to page 23, first

Art Unit: 1634

paragraph), “recombination site” is defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see page 25, last paragraph), and “recombinant protein” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph). Atlung *et al.*, teach to construct plasmid pTAC3599 by cloning a 740-bp Taq I fragment containing the promoter appYp into the Sama I site of pTAC3575 (see Figure 1 in page 12). Since the restriction sites of the 740-bp Taq I fragment containing the promoter appYp is recombination sites, Atlung *et al.*, disclose inserting one or more integration sequences comprising at least one recombination site (ie., the 740-bp Taq I fragment containing the promoter appYp) into at least one nucleic acid molecule (ie., pTAC3575) as recited in claim 16. Since Atlung *et al.*, teach to ligate the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion to the purified BstEII-Sal I fragment carrying the attP-aphA cassette from pTAC3463 (see page 13, left column and Figure 2 in page 14) and it is known that a ligation reaction must be performed in the presence of a ligase, a nucleic acid molecule that is produced by inserting one or more integration sequences comprising at least one recombination site (ie., the 740-bp Taq I fragment containing the promoter appYp) into at least one nucleic acid molecule (ie., pTAC3575) and has the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion taught by Atlung *et al.*, comprises at least first (ie., BstE II site) and a second recombination sites (ie., Xho I site) as recited in claim 16 and Atlung *et al.*, disclose causing said at least first and second recombination sites (ie., BstE II and Xho I sites of the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion) to recombine in the presence of at least one recombination protein

Art Unit: 1634

(ie., the ligase) as recited in claim 16. Since the restriction sites of the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion taught by Atlung *et al.*, are located on 5' and 3' ends of the fragment, Atlung *et al.*, disclose that said first and second recombination sites are separated by a portion of said integration-sequence-containing nucleic acid molecule as recited in claim 18.

Regarding claims 15 and 27, since the purified BstE II-Xho I fragment of pTAC3599 carries the *phoA* gene and the *appYp-lacZ* fusion, Atlung *et al.*, disclose that said nucleic acid molecule is genomic DNA as recited in claims 15 and 27.

Regarding claim 17, Since Atlung *et al.*, teach to ligate the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion to the purified BstEII-Sal I fragment carrying the *attP-aphA* cassette from pTAC3463 and generate a ligated circular molecule (see page 13, left column and Figure 2 in page 14), Atlung *et al.*, disclose that said recombination of said first and second recombination sites results in a circular molecule as recited in claim 17.

Regarding claims 19 and 20, since the integration sequences comprising at least one recombination site (ie., the 740-bp Taq I fragment containing the promoter *appYp*) taught by Atlung *et al.*, has an *appYp* (acid phosphatase transcriptional activator gene, see left column in page 11), according to the definition of "selectable markers" in the specification (see page 26, last paragraph bridging to page 27, first paragraph), Atlung *et al.*, disclose that said integration sequence comprises one selectable marker (ie., *appYp*) as recited in claims 19 and 20.

Regarding claims 32 and 33, since Atlung *et al.*, teaches that said first and second recombination sites are 5' and 3' ends of restriction sites (ie., BstE II and Xho I sites) (see

Art Unit: 1634

above), Atlung *et al.*, discloses that said first and second recombination sites are site-specific recombination sites as recited in claims 32 and 33.

Regarding claim 44, according to the specification, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule” (see the specification, page 22, last paragraph bridging to page 23, first paragraph), “recombination site” is defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see page 25, last paragraph), and “recombinant protein” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph). Since Atlung *et al.*, teach to generate the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion, Atlung *et al.*, disclose obtaining a first nucleic acid molecule comprising at least a first segment (ie., purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion) which comprises at least a first and a second recombination site (ie., BstE II and Xho I sites) wherein said segment comprises at least one integration sequence as recited in step (a) of claim 44. Since Atlung *et al.*, teach the purified BstEII-Sal I fragment carrying the attP-aphA cassette from pTAC3463, Atlung *et al.*, disclose a second nucleic acid molecule comprising at least third and fourth recombination sites (ie., BstEII and Sal I sites) as recited in step (b) of the claim. Since, during the ligation reaction, the purified BstE II-Xho I fragment of pTAC3599 carrying the phoA gene and the appYp-lacZ fusion must mixed with the purified BstEII-Sal I fragment carrying the attP-aphA cassette from pTAC3463 in the presence of a ligase, Atlung *et al.*, disclose forming a mixture by mixing said first nucleic acid molecule (ie., the purified BstE II-Xho I fragment of

Art Unit: 1634

pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion) with at least one second nucleic acid molecule comprising at least a third and fourth recombination site (ie., the purified BstEII-Sal I fragment carrying the *attP-aphA* cassette from pTAC3463) in the presence of at least one recombination protein (ie., the ligase), and incubating said mixture under conditions favoring recombination at least between said first (ie., BstE II site from the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion) and third recombination sites (ie., BstE II site from the purified BstEII-Sal I fragment carrying the *attP-aphA* cassette from pTAC3463) and at least between said second (ie., Xho I site from the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion) and fourth recombination sites (ie., Sal I site from the purified BstEII-Sal I fragment carrying the *attP-aphA* cassette from pTAC3463) thereby transferring said first segment (ie., the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion) from said first nucleic acid molecule to said second nucleic molecule as recited in steps (b) and (c) of claim 44.

Regarding claims 45 and 46, since 3' and 5' of the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion taught by Atlung *et al.*, has restriction sites (see above), Atlung *et al.*, teaches that said first segment (ie., the purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the *appYp-lacZ* fusion) is flanked on one side by said first recombination site and is flanked on the other side by said second recombination site as recited in claim 45 wherein said recombination sites are site-specific recombination sites as recited in claim 46.

Regarding claim 57, since the ligation reaction taught by Atlung *et al.*, is performed in *in*

Art Unit: 1634

vitro (see Table 1 in page 13 and Figure 2 in page 14), Atlung *et al.*, discloses that said recombination (ie., the ligation taught by Atlung *et al.*,) takes place in vitro as recited in claim 57.

Therefore, Atlung *et al.*, teach all limitations recited in claims 14-20, 27, 32, 33, 44-46, and 57.

Response to Arguments

In page 19, second paragraph bridging to page 22, second paragraph of applicant remarks, applicant argued that: (1) “[A]tlung fails to disclose integration sequences according to the present invention” in view of the definition of “integration sequences”; and (2) “ligation sites (or, more accurately, restriction sites) do not qualify as enzyme that binds ligation sites (or the restriction enzyme that cleaves at restriction sites) does not ‘have both endonuclease and ligase properties’ and does not ‘exchange DNA segments’ .”

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. First, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule” (see the specification, page 22, last paragraph bridging to page 23, first paragraph). Since purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the appYp-lacZ fusion taught by Atlung *et al.*, is considered as an integration sequence in the rejection and applicant does not provide an evidence to show why purified BstE II-Xho I fragment of pTAC3599 carrying the *phoA* gene and the appYp-lacZ fusion can not be inserted randomly into a target nucleic acid molecule, Atlung *et al.*, do teach integration sequences. Furthermore, it is known that a DNA can be randomly inserted in the genome of a cell if the DNA is microinjected into the cell. Second,

Art Unit: 1634

since “recombination site” was defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see specification, page 23, last paragraph), ligation sites (restriction sites) can be considered as “recombination sites”. Third, although site-specific recombinases are proteins that are present in many organisms (e.g., viruses and bacteria) and have been characterized as having endonuclease and ligase properties (see the specification, page 2, first paragraph), the rejected claims do not require site-specific recombinases. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

9. Claims 14-20, 27, 32-51, and 57 are rejected under 35 U.S.C. 102(a) or 102 (e) as being anticipated by Hartley *et al.*, (US Patent No. 5,888,732, filed on June 7, 1996 and published on March 30, 1999).

Hartley *et al.*, teach recombinational cloning using engineered recombination sites.

Regarding claim 14, according to the specification, “integration sequence” is defined as “any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule” (see the specification, page 22, last paragraph bridging to page 23, first paragraph), “recombination site” is defined as “a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins” (see page 25, last paragraph), and “recombinant protein” is defined as “proteins that are involved in recombination reactions involving one or more recombination sites” (see the specification, page 25, second paragraph). Hartley *et al.*, teach a method of making chimeric DNA, which

Art Unit: 1634

comprises: (a) combining *in vitro* or *in vivo* (i) an Insert Donor DNA molecule, comprising a desired DNA segment flanked by a first recombination site and a second recombination site, wherein the first and second recombination sites do not recombine with each other; (ii) a Vector Donor DNA molecule containing a third recombination site and a fourth recombination site, wherein the third and fourth recombination sites do not recombine with each other; and (iii) one or more site specific recombination proteins capable of recombining the first and third recombinational sites and/or the second and fourth recombinational sites; thereby allowing recombination to occur, so as to produce at least one Cointegrate DNA molecule, at least one desired Product DNA molecule which comprises said desired DNA segment, and optionally a Byproduct DNA molecule; and then, optionally, (b) selecting for the Product or Byproduct DNA molecule (see column 4, lines 47-67, column 5, line 1, and Figures 1, 2A, 3A, and 4A). Since Hartley *et al.*, teach an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site, Hartley *et al.*, disclose one or more integration sequences comprising at least one recombination site as recited in claim 14. Since Hartley *et al.*, teach to form at least one Cointegrate DNA molecule in at least one Cointegrate DNA molecule in the presence of an Insert Donor DNA molecule, a Vector Donor DNA molecule, and one or more site specific recombination proteins, Hartley *et al.*, disclose inserting one or more integration sequences comprising at least one recombination site (ie., an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site) into at least one nucleic acid molecule (ie., the Vector Donor DNA molecule taught by Hartley *et al.*,) to produce one or more integration sequence-containing nucleic acid molecules as recited in claim 14. Since Hartley *et al.*, teach that, in the

Art Unit: 1634

presence of a recombinase, the Cointegrate DNA molecule further forms least one desired Product DNA molecule which comprises said desired DNA segment with recombination sites (ie., attR and loxP in Figure 2A) and optionally a Byproduct DNA molecule (see Figures 1 and 2A), Hartley *et al.*, disclose transferring one or more integration sequence-containing nucleic acid molecules comprising recombination sites (ie., a nucleic acid from the Cointegrate DNA molecule with attR and loxP) into one or more vectors (ie., intprod in Figure 2) in the presence of one or more recombination proteins as recited in claim 14.

Regarding claim 16, since Hartley *et al.*, teach to insert an Insert Donor DNA molecule into a Vector Donor DNA molecule and form at least one Cointegrate DNA molecule in at least one Cointegrate DNA molecule in the presence of one or more site specific recombination proteins wherein the Insert Donor DNA molecule comprises a desired DNA segment flanked by a first recombination site and a second recombination site (see column 4, lines 46-67 and Figures 1, 2A, 3A, and 4A), Hartley *et al.*, disclose inserting one or more integration sequences (ie., the Insert Donor DNA molecule comprises a desired DNA segment flanked by a first recombination site and a second recombination site taught by Hartley *et al.*), said one or more integration sequences comprising at least one recombination site, into at least one nucleic acid molecule (ie., Vector Donor DNA molecule taught by Hartley *et al.*) thereby producing an integration sequence-containing nucleic acid molecule (ie., pEVC7cointegr in Figure 2) comprising at least a first and a second recombination site (ie., attR and loxP); and causing said at least first and second recombination sites to recombine in the presence of at least one recombination protein (ie., Cre in Figure 2) as recited in claim 16.

Regarding claims 15 and 27, since Hartley *et al.*, teach that pEVC726 contains kanamycin

Art Unit: 1634

resistance gene, Hartley *et al.*, disclose that said nucleic acid molecule is genomic DNA or cDNA as recited in claims 15 and 27.

Regarding claims 17 and 18, since Hartley *et al.*, teach the first and second recombination sites of pEZC705 (ie., attR and loxP) recombine with the third and fourth recombination sites of pEZC726 (ie., attP and loxP) to form pEZC7 cointegr (see Figure 2A), Hartley *et al.*, disclose that said recombination of said first and second recombination sites results in a circular molecule as recited in claim 17 wherein said first and second recombination sites (ie., att R and loxP) are separated by at least a portion of said integration sequence-containing nucleic acid as recited in claim 18 (see pEZC705 in Figure 2A).

Regarding claims 19 and 20, since the integration sequences (ie., the Insert Donor DNA molecule such as pEZC705) taught by Hartley *et al.*, has amp (an amplification resistance gene), according to the definition of “selectable markers” in the specification (see page 26, last paragraph bridging to page 27, first paragraph), Hartley *et al.*, *et al.*, disclose that said integration sequence comprises one selectable marker (ie., amp) as recited in claims 19 and 20.

Regarding claims 32-39, since Hartley *et al.*, teach that the first and second recombination sites are attR and loxP respectively (see pEZC7cointegr in Figure 2A), Hartley *et al.*, disclose that said first and second recombination sites are site-specific recombination sites as recited in claims 32 and 33, said recombination sites are selected from the group consisting of loxp, attB, attP, attL, attR, FRT, a recombination site recognized by a resolvase, a bacterial transposable element, an integrating virus, an IS element, a P element of *Drosophila*, a bacterial virulence factor and a mobile genetic element for an eukaryotic organism, or mutants or derivatives thereof as recited in claim 34, said recombination sites are selected from the group

Art Unit: 1634

consisting of loxP, attB, attP, attL, attR, FRT, a recombination site recognized by a resolvase, a bacterial transposable element, an integrating virus, an IS element, a P element of *Drosophila*, a bacterial virulence factor and a mobile genetic element for an eukaryotic organism as recited in claim 35, at least one of said first and said second recombination sites is an att site or a mutant or derivative thereof as recited in claim 36, at least one of said first and said second recombination sites is an att site as recited in claim 37, said att site is selected from the group consisting of attB, attP, attL and attR, or a mutant or derivative thereof as recited in claim 38, said att site is selected from the group consisting of attB, attP, attL and attR as recited in claim 39.

Regarding claim 44, since Hartley *et al.*, teach an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site, Hartley *et al.*, disclose obtaining a first nucleic acid molecule (ie., the Insert Donor DNA) comprising at least a first segment which comprises at least a first and a second recombination site (ie., a desired DNA segment flanked by a first recombination site and a second recombination site) wherein said segment comprises at least one integration sequence as recited in step (a) of claim 44. Since Hartley *et al.*, teach to insert an Insert Donor DNA molecule into a Vector Donor DNA molecule and form at least one Cointegrate DNA molecule in at least one Cointegrate DNA molecule in the presence of one or more site specific recombination proteins capable of recombining the first and third recombinational sites and/or the second and fourth recombinational sites wherein the Vector Donor DNA molecule containing a third recombination site and a fourth recombination site (see column 4, lines 46-67 and Figures 1, 2A, 3A, and 4A), Hartley *et al.*, disclose forming a mixture by mixing said first nucleic acid molecule (ie., the Insert Donor DNA molecule taught by Hartley *et al.*,) with at least one second nucleic

Art Unit: 1634

acid molecule comprising at least a third and fourth recombination site (ie., the Vector Donor DNA molecule taught by Hartley *et al.*) in the presence of at least one recombination protein, and incubating said mixture under conditions favoring recombination at least between said first and third recombination sites and at least between said second and fourth recombination sites, thereby transferring said first segment from said first nucleic acid molecule (ie., see nucleic acid segment from pEZC705 in PEZC7ointegr in Figure 2) from to said second nucleic molecule (ie., the Vector Donor DNA molecule taught by Hartley *et al.*) as recited in claim 44.

Regarding claim 45, since Hartley *et al.*, teach that there is a nucleic acid segment between attB (ie., a first recombination site) and loxP (ie., a second recombination site), Hartley *et al.*, disclose said first segment is flanked on one side by said first recombination site and is flanked on the other side by said second recombination site as recited by claim 45.

Regarding claims 46-51, since Hartley *et al.*, teach that the first and second recombination sites are attB and loxP respectively (see pEZC705 in Figure 2A), Hartley *et al.*, disclose that said first and second recombination sites are site-specific recombination sites as recited in claim 46, said recombination sites are selected from the group consisting of loxP, attB, attP, attL, attR, FRT, a recombination site recognized by a resolvase, a bacterial transposable element, an integrating virus, an IS element, a P element of *Drosophila*, a bacterial virulence factor and a mobile genetic element for an eukaryotic organism as recited in claim 47, at least one of said first and said second recombination sites is an att site or a mutant or derivative thereof as recited in claim 48, at least one of said recombination sites is an att site as recited in claim 49, said att site is selected from the group consisting of attB, attP, attL and attR, or a

Art Unit: 1634

mutant or derivative thereof as recited in claim 50, said att site is selected from the group consisting of attB, attP, attL and attR as recited in claim 51.

Regarding claim 57, since the recombination reaction taught by Hartley *et al.*, is performed in vitro (see column 4, lines 46-67), Hartley *et al.*, disclose that said recombination takes place in vitro as recited in claim 57.

Therefore, Hartley *et al.*, teach all limitations recited in claims 14-20, 27, 32-39, 44-51, and 57.

Response to Arguments

In page 22, third paragraph bridging to page 24, second paragraph of applicant's remarks, applicant argues that "[H]artley does not disclose the insertion of one or more integration sequences into at least one nucleic acid molecule or a nucleic acid segment comprising at least one integration sequence" in view of the definition of "integration sequence".

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. According to the specification, "integration sequence" is defined as "any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule" (see the specification, page 22, last paragraph bridging to page 23, first paragraph). Since Hartley *et al.*, teach an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site and Hartley *et al.*, disclose one or more integration sequences comprising at least one recombination site (ie., an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site) as recited in claim 14. Furthermore, applicant does not provide an evidence to show why the Insert Donor DNA molecule comprising a desired DNA segment

Art Unit: 1634

flanked by a first recombination site and a second recombination site taught by Hartley *et al.*, can not be inserted randomly into a target nucleic acid molecule. In fact, it is known that a DNA can be randomly inserted in the genome of a cell if the DNA is microinjected into the cell. Second, the rejected claims do not require at least one nucleic acid molecule or a nucleic acid segment comprising at least one integration sequence as suggested by applicant.

10. Claims 14-20, 27, 32-39, 44-51, and 57 are rejected under 35 U.S.C. 102(f) because the applicant did not invent the claimed subject matter.

The above patent (US Patent No. 5,888,732) was filed on June 7, 1996 and published on March 30, 1999 and taught all limitations recited in claims 14, 16-20, and 30-43 (see above). However, Gary Temple is not listed in above patent, he can not considered as inventor of this instant application. Please give explanation.

Response to Arguments

In page 23, third paragraph bridging to page 25, second paragraph of applicant's remarks, applicant argues that "[H]artley fails to disclose the use of integration sequences" since "the invention claimed in Hartley is not identical to that claimed in present claims 14-20, 27, 32-39, 44-51, and 57".

This argument has been fully considered but it is not persuasive toward the withdrawal of the rejection because US Patent No. 5,888,732 does disclose the use of integration sequences (see above).

Double Patenting

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12. Claims 14-20, 27, 32-39, 44-51, and 57 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 27-39 of U.S. Patent No.5,888,732. An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but examined claims in this instant application are not patentably distinct from the reference claims because the examined claims are either anticipated by, or would have been obvious over, the reference claims. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). Although independent claims 14-20, 27, 32-39, 44-51, and 57 in this instant application are not

Art Unit: 1634

identical to claims 27-39 of U.S. Patent No. 5,888,732, 27-39 of U.S. Patent No. 5,888,732 are directed to the same subject matter and fall entirely within the scope of claims 14-20, 27, 32-39, 44-51, and 57 in this instant application. In other words, claims 14-20, 27, 32-39, 44-51, and 57 in this instant application are anticipated by claims 27-39 of U.S. Patent No. 5,888,732.

Response to Arguments

In page 24, third and fourth paragraphs of applicant's remarks, applicant argues that, "[F]or the reasons discussed above distinguishing the presently claimed invention from the disclosure of Hartley, Applicants respectfully disagree with the Examiner's contention that the claims of the present invention are not patentably distinct from claims 27-39 of Hartley."

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. According to the specification, "integration sequence" is defined as "any nucleotide sequence that is capable of inserting randomly into a target nucleic acid molecule" (see the specification, page 22, last paragraph bridging to page 23, first paragraph). Since claims 27-39 of U.S. Patent No. 5,888,732 teach an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site and claims 27-39 of U.S. Patent No. 5,888,732 disclose one or more integration sequences comprising at least one recombination site as recited in claims 14 and 16.

Conclusion

13. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1634

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

14. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

(1) The prior art that can be used for rejections under 35 U.S.C. 102(e) or 102(f) and double patenting:

Hartley et al., (U.S. Patent Nos. 6,171,861 B1, 6,270,969, and 6,277,608)

(2) The prior art that can be used for rejections under 35 U.S.C. 102(e) or 102(f):

Hartley et al., (U.S. Patent No. 6,143,557)

15. No claim is allowed.

16. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 308-4242.

Art Unit: 1634


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746.

The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (571)272-0782.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu
PSA
October 19, 2004


KENNETH R. HORLICK, PH.D.
PRIMARY EXAMINER

10/25/04